Novogene Co., Ltd.

Shanghai Stock Exchange 688315.SS

Novogene Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.01

Novogene Co., Ltd. Debt to Equity Ratio is 0.01 for the year ending December 31, 2023, a -71.14% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Novogene Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.03, a 0.29% change year over year.
  • Novogene Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.03, a -60.83% change year over year.
  • Novogene Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.06, a -62.11% change year over year.
  • Novogene Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.17, a 0.00% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
SV Wall Street
Shanghai Stock Exchange: 688315.SS

Novogene Co., Ltd.

CEO Dr. Ruiqiang Li
IPO Date April 13, 2021
Location China
Headquarters Building 301
Employees 2,144
Sector Healthcare
Industries
Biotechnology Big Data Database
Description

Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novogene Co., Ltd. has a strategic partnership with Hummingbird Bioscience Pte. Ltd. to support the development of investigational drug candidate HMBD-001, an anti-HER3 antibody to be evaluated for treatment of various tumor types, including NRG1-fusion driven cancers. The company was founded in 2011 and is headquartered in Beijing, China.

Similar companies

ONT.L

Oxford Nanopore Technologies plc

USD 1.81

0.53%

StockViz Staff

February 3, 2025

Any question? Send us an email